Therapeutic cell engineering with surface-conjugated synthetic nanoparticles (original) (raw)

• Fiorina, P., Shapiro, A.M., Ricordi, C. & Secchi, A. The clinical impact of islet transplantation. Am. J. Transplant. 8, 1990–1997 (2008).
  Article CAS Google Scholar
• Alison, M.R., Islam, S. & Lim, S.M. Cell therapy for liver disease. Curr. Opin. Mol. Ther. 11, 364–374 (2009).
  CAS PubMed Google Scholar
• Alper, J. Geron gets green light for human trial of ES cell–derived product. Nat. Biotechnol. 27, 213–214 (2009).
  Article CAS Google Scholar
• Dimos, J.T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons 321, 1218–1221 (2008).
• Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
  Article CAS Google Scholar
• Hunder, N.N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698–2703 (2008).
  Article CAS Google Scholar
• Mackinnon, S., Thomson, K., Verfuerth, S., Peggs, K. & Lowdell, M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol. Dis. 40, 63–67 (2008).
  Article CAS Google Scholar
• Zeng, R. et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201, 139–148 (2005).
  Article CAS Google Scholar
• Wallace, A. et al. Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966–3974 (2008).
  Article CAS Google Scholar
• Trowbridge, J.J., Xenocostas, A., Moon, R.T. & Bhatia, M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat. Med. 12, 89–98 (2006).
  Article CAS Google Scholar
• Berger, C. et al. Safety and immunological effects of IL-15 administration in nonhuman primates. Blood 114, 2417–2426 (2009).
  Article CAS Google Scholar
• Thompson, J.A. et al. Recombinant interleukin 2 toxicity, pharmacokinetics and immunomodulatory effects in a phase I trial. Cancer Res. 47, 4202–4207 (1987).
  CAS PubMed Google Scholar
• Treisman, J. et al. Interleukin-2–transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85, 139–145 (1995).
  CAS PubMed Google Scholar
• Sahaf, B., Heydari, K., Herzenberg, L.A. & Herzenberg, L.A. Lymphocyte surface thiol levels. Proc. Natl. Acad. Sci. USA 100, 4001–4005 (2003).
  Article CAS Google Scholar
• Bernstein, I.D., Boyd, R.L. & van den Brink, M.R. Clinical strategies to enhance posttransplant immune reconstitution. Biol. Blood Marrow Transplant. 14, 94–99 (2008).
  Article Google Scholar
• Jain, R.K. A new target for tumor therapy. N. Engl. J. Med. 360, 2669–2671 (2009).
  Article CAS Google Scholar
• Overwijk, W.W. et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of 'self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188, 277–286 (1998).
  Article CAS Google Scholar
• Rubinstein, M.P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc. Natl. Acad. Sci. USA 103, 9166–9171 (2006).
  Article CAS Google Scholar
• Lu, J. et al. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 8, 3877–3884 (2002).
  CAS PubMed Google Scholar
• Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808–813 (2009).
  Article CAS Google Scholar
• Dinauer, N. et al. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T lymphocytes. Biomaterials 26, 5898–5906 (2005).
  Article CAS Google Scholar
• Davis, M.E., Chen, Z.G. & Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008).
  Article CAS Google Scholar
• Prescher, J.A., Dube, D.H. & Bertozzi, C.R. Chemical remodelling of cell surfaces in living animals. Nature 430, 873–877 (2004).
  Article CAS Google Scholar
• Reddy, S.T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159–1164 (2007).
  Article CAS Google Scholar
• Woodrow, K.A. et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater. 8, 526–533 (2009).
  Article CAS Google Scholar
• Bin Na, H., Song, I.C. & Hyeon, T. Inorganic nanoparticles for MRI contrast agents. Adv. Mater. 21, 2133–2148 (2009).
  Article Google Scholar
• Tong, R. et al. Nanopolymeric therapeutics. MRS Bull. 34, 422–431 (2009).
  Article CAS Google Scholar
• Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A. & Davis, M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 104, 15549–15554 (2007).
  Article CAS Google Scholar
• Weissleder, R., Kelly, K., Sun, E.Y., Shtatland, T. & Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418–1423 (2005).
  Article CAS Google Scholar
• Dhar, S., Gu, F.X., Langer, R., Farokhzad, O.C. & Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA 105, 17356–17361 (2008).
  Article CAS Google Scholar
• Kirpotin, D.B. et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732–6740 (2006).
  Article CAS Google Scholar
• Reichardt, W. et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J. Immunol. 181, 4770–4779 (2008).
  Article CAS Google Scholar